Blair McNamara

513 total citations
34 papers, 238 citations indexed

About

Blair McNamara is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Blair McNamara has authored 34 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Reproductive Medicine and 8 papers in Obstetrics and Gynecology. Recurrent topics in Blair McNamara's work include Ovarian cancer diagnosis and treatment (11 papers), HER2/EGFR in Cancer Research (8 papers) and Reproductive Health and Contraception (5 papers). Blair McNamara is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), HER2/EGFR in Cancer Research (8 papers) and Reproductive Health and Contraception (5 papers). Blair McNamara collaborates with scholars based in United States, Italy and Ireland. Blair McNamara's co-authors include Alessandro D. Santin, Levent Mutlu, Jennifer Kerns, Diego Manavella, Miriam Kuppermann, Giuseppe Gullo, Pasquale Patrizio, Tobias M.P. Hartwich, Vanessa K. Dalton and Holly Powell Kennedy and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Molecules.

In The Last Decade

Blair McNamara

28 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Blair McNamara United States 9 86 76 60 52 42 34 238
Kyung Hee Han South Korea 9 129 1.5× 105 1.4× 74 1.2× 27 0.5× 23 0.5× 15 326
Nura Fitnat Topbaş Selçuki Türkiye 9 102 1.2× 67 0.9× 31 0.5× 28 0.5× 29 0.7× 34 238
Evelyn Cantillo United States 8 68 0.8× 45 0.6× 88 1.5× 64 1.2× 85 2.0× 38 277
Kathryn Hunt United Kingdom 7 99 1.2× 35 0.5× 36 0.6× 78 1.5× 38 0.9× 12 354
Olivia Foley United States 8 82 1.0× 110 1.4× 41 0.7× 71 1.4× 19 0.5× 27 284
Mackenzie W. Sullivan United States 9 50 0.6× 37 0.5× 32 0.5× 53 1.0× 23 0.5× 33 222
Michele Paudice Italy 9 91 1.1× 48 0.6× 38 0.6× 71 1.4× 31 0.7× 47 246
Neil T. Phippen United States 11 71 0.8× 65 0.9× 47 0.8× 85 1.6× 27 0.6× 30 286
Yasuhiko Shiki Japan 8 115 1.3× 64 0.8× 40 0.7× 35 0.7× 38 0.9× 32 236

Countries citing papers authored by Blair McNamara

Since Specialization
Citations

This map shows the geographic impact of Blair McNamara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Blair McNamara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Blair McNamara more than expected).

Fields of papers citing papers by Blair McNamara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Blair McNamara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Blair McNamara. The network helps show where Blair McNamara may publish in the future.

Co-authorship network of co-authors of Blair McNamara

This figure shows the co-authorship network connecting the top 25 collaborators of Blair McNamara. A scholar is included among the top collaborators of Blair McNamara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Blair McNamara. Blair McNamara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bellone, Stefania, Tobias M.P. Hartwich, Blair McNamara, et al.. (2025). Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications. 5(5). 774–782. 1 indexed citations
2.
3.
Bellone, Stefania, Blair McNamara, Natália Buza, et al.. (2025). Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications. 5(9). 1611–1620.
4.
5.
6.
McNamara, Blair, Stefania Bellone, Levent Mutlu, et al.. (2024). Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology. 189. 16–23. 7 indexed citations
7.
McNamara, Blair, Tobias M.P. Hartwich, Diego Manavella, et al.. (2024). Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology. 183. 133–140. 11 indexed citations
8.
McNamara, Blair, Tobias M.P. Hartwich, Diego Manavella, et al.. (2024). Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology. 187. 12–20. 5 indexed citations
9.
Han, Chanhee, Blair McNamara, Stefania Bellone, et al.. (2023). The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology. 170. 172–178. 5 indexed citations
10.
McNamara, Blair, et al.. (2023). HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers. 15(16). 4085–4085. 4 indexed citations
11.
McNamara, Blair, Levent Mutlu, Tobias M.P. Hartwich, et al.. (2023). Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal of Molecular Sciences. 24(10). 8873–8873. 8 indexed citations
12.
McNamara, Blair, et al.. (2023). Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal of Women s Health. Volume 15. 1353–1365. 6 indexed citations
13.
McNamara, Blair, et al.. (2023). Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules. 28(21). 7389–7389. 9 indexed citations
14.
Santin, Alessandro D., Blair McNamara, Eric R. Siegel, et al.. (2023). Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.. Journal of Clinical Oncology. 41(16_suppl). 5599–5599. 12 indexed citations
15.
Mutlu, Levent, Diego Manavella, Giuseppe Gullo, et al.. (2022). Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers. 14(21). 5187–5187. 49 indexed citations
16.
McNamara, Blair, et al.. (2021). Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology Reports. 38. 100870–100870. 1 indexed citations
17.
Webster, Emily, Ghanshyam S. Yadav, Stefan Gysler, et al.. (2020). Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports. 34. 100667–100667. 8 indexed citations
18.
Kerns, Jennifer, Alexis Light, Vanessa K. Dalton, et al.. (2018). Decision satisfaction among women choosing a method of pregnancy termination in the setting of fetal anomalies and other pregnancy complications: A qualitative study. Patient Education and Counseling. 101(10). 1859–1864. 22 indexed citations
19.
McNamara, Blair, et al.. (2018). “I’m used to doing it by myself”: exploring self-reliance in pregnancy. BMC Pregnancy and Childbirth. 18(1). 393–393. 2 indexed citations
20.
McNamara, Blair, et al.. (2017). “I Just Don't Know”: An Exploration of Women's Ambivalence about a New Pregnancy. Women s Health Issues. 28(1). 75–81. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kyung Hee Han Breakdown of academic impact, for papers by Nura Fitnat Topbaş Selçuki Breakdown of academic impact, for papers by Evelyn Cantillo Breakdown of academic impact, for papers by Kathryn Hunt Breakdown of academic impact, for papers by Olivia Foley Breakdown of academic impact, for papers by Mackenzie W. Sullivan Breakdown of academic impact, for papers by Michele Paudice Breakdown of academic impact, for papers by Neil T. Phippen Breakdown of academic impact, for papers by Yasuhiko Shiki
Rankless by CCL
2026